Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma

SK. Kumar, FK. Buadi, B. LaPlant, A. Halvorson, N. Leung, P. Kapoor, D. Dingli, MA. Gertz, RS. Go, PL. Bergsagel, Y. Lin, A. Dispenzieri, YL. Hwa, A. Fonder, M. Hobbs, R. Fonseca, SR. Hayman, AK. Stewart, JA. Lust, J. Mikhael, W. Gonsalves, C....

. 2018 ; 8 (8) : 70. [pub] 20180730

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze I, klinické zkoušky, fáze II, časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012509

Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41-88); 29% had high or intermediate risk FISH. The MTD was 400 mg/m2 of cyclophosphamide weekly. The best confirmed response in all 48 patients included ≥ partial response in 77%, including ≥ VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012509
003      
CZ-PrNML
005      
20210803094952.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-018-0106-3 $2 doi
035    __
$a (PubMed)30061664
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kumar, Shaji K $u Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
245    10
$a Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma / $c SK. Kumar, FK. Buadi, B. LaPlant, A. Halvorson, N. Leung, P. Kapoor, D. Dingli, MA. Gertz, RS. Go, PL. Bergsagel, Y. Lin, A. Dispenzieri, YL. Hwa, A. Fonder, M. Hobbs, R. Fonseca, SR. Hayman, AK. Stewart, JA. Lust, J. Mikhael, W. Gonsalves, C. Reeder, T. Skacel, SV. Rajkumar, MQ. Lacy,
520    9_
$a Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41-88); 29% had high or intermediate risk FISH. The MTD was 400 mg/m2 of cyclophosphamide weekly. The best confirmed response in all 48 patients included ≥ partial response in 77%, including ≥ VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a sloučeniny boru $x aplikace a dávkování $7 D001896
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glycin $x aplikace a dávkování $x analogy a deriváty $7 D005998
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x diagnóza $x farmakoterapie $x mortalita $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Buadi, Francis K $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a LaPlant, Betsy $u Department of Biostatistics, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Halvorson, Alese $u Department of Biostatistics, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Leung, Nelson $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Kapoor, Prashant $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Dingli, David $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Gertz, Morie A $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Go, Ronald S $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Bergsagel, P Leif $u Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
700    1_
$a Lin, Yi $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Dispenzieri, Angela $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Hwa, Yi Lisa $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Fonder, Amie $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Hobbs, Miriam $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Fonseca, Rafael $u Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
700    1_
$a Hayman, Suzanne R $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Stewart, A Keith $u Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
700    1_
$a Lust, John A $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Mikhael, Joseph $u Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
700    1_
$a Gonsalves, Wilson $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Reeder, Craig $u Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
700    1_
$a Skácel, Tomáš $u Takeda Pharmaceutical Company Limited, Osaka, Japan. 31st Medical Department Clinical Department of Haematology of the First Faculty of Medicine and General, Teaching Hospital Charles University, Praha, Czech Republic. Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, Praha, Czech Republic. $7 xx0262694
700    1_
$a Rajkumar, S Vincent $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
700    1_
$a Lacy, Martha Q $u Division of Hematology, Mayo Clinic, Rochester, MN, USA.
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 8, č. 8 (2018), s. 70
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30061664 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20210803094948 $b ABA008
999    __
$a ok $b bmc $g 1391819 $s 1050814
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 8 $c 8 $d 70 $e 20180730 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20190405
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace